Skip to main content

Regenovo

HardwareHangzhou (Qiantang District, Xiasha; 呈瑞街259号3幢101室), Zhejiang, ChinaFounded 2013· One of 1733 Hardware companies tracked by AMPulse

Develops medical-grade 3D bioprinters and bioinks for creating living tissue scaffolds, enabling applications in drug screening, regenerative medicine, and personalized medical devices

CEO / Founder
Xu Mingen
Team Size
51-200
Stage
Active
Total Funding
>$15M (partial; later rounds undisclosed)
Latest Round
Venture Round
Key Investors
Xu Mingen (~28% largest shareholder); Shining3D / 先临三维 (~17%, no longer controlling); Proya / 珀莱雅; Zheshang Venture Capital / 浙商创投; Puhua Capital / 普华资本; Qinbing Investment / 秦兵投资; Hewan Investment / 和湾投资; Qiantang Industry Group / 钱塘产业集团; Zhejiang Rongsheng Holdings; Hangzhou Economic Development Zone VC; Peng Rui Group / 鹏瑞集团; other private investors

Technology & Products

Key Products

Regenovo 3D Bioprinters (e.g., Bio-Architect X), bioinks, biomaterials, skin models, micro-liver models.

Technological Advantage

Patented technology for real-time cell microenvironment monitoring (verified); proprietary bioink formulations and precision control systems (claimed); complete digital medical chain from medical information to 3D printed medical products

Patent position

Regenovo filed 2 patent families in 2022–2024, versus 5 in 2019–2021; its filings fell 60%, while tracked AM filings in the same patent offices were unchanged at 0%, leaving Regenovo below that trend. AMPulse analysis

Filing momentum
2 families filed 2022–2024, 5 in 2019–2021 (-60%); all tracked AM filings in the same offices 0%
Filed in
CN 77%WO 10%EP 10%US 10%
Named competitors, AM patent families
CELLINK 52ROKIT Healthcare 80

30 AM patent families in total. Recent years are still being published, so read a filing change against the same-office figure.

Differentiation

Value Proposition

Provides complete biological 3D printing solutions from equipment to materials, reducing tissue engineering development time and enabling personalized medical treatments

How They Differentiate

Focus on real-time cell microenvironment monitoring (unique among competitors); complete solution from printers to biomaterials vs competitors' narrower focus; strong academic partnerships in China vs global competitors' different geographic focus

Market & Competition

Target Customers

Pharmaceutical companies, research institutions, hospitals, and medical device manufacturers

Industry Verticals

Pharmaceutical; Medical Research; Healthcare; Biotechnology

Competitors

Organovo, CELLINK, Rokit Healthcare

Growth & Milestones

Growth Metrics

Developed China's first commercial 3D bioprinter in 2013; Over 50 bioprinters installed in research institutions and hospitals across China; Published more than 100 research papers in bioprinting field; Received multiple national and provincial research grants

Major Milestones

Founded in 2013 as joint venture by Xiangli 3D; Developed world's first real-time cell microenvironment monitoring 3D printer; Hosted 5th Regenovo Biological 3D Printing Summit in 2021; Achieved national-level specialized and innovative enterprise status

Notable Customers

Hangzhou University of Science and Technology; Zhejiang University School of Medicine; Shanghai Ninth People's Hospital; Chinese Academy of Sciences

https://www.regenovo.com

AM patents

AM-relevant patents linked to this company.

Patents
32
Granted
20
Families
30

Leading domains: process (32), equipment (20), application (7)

Filings by year: 2022: 3 · 2021: 3 · 2019: 3 · 2018: 4 · 2017: 8 · 2016: 6

  1. 3D PRINTING CONTROL METHOD AND APPARATUS, AND ELECTRONIC DEVICE2023134028 · WO
  2. Bone tissue repair ink, composition and bracket, and preparation methods thereof as well as kit109381749 · CN
  3. Low-temperature printing platform and 3D printing equipment applying same105500711 · CN
  4. ON-LINE MONITORING METHOD AND SYSTEM FOR THREE-DIMENSIONAL PRINTING03459716 · EP
  5. Multi-nozzle biological 3D printing equipment with multi-axis robot and application method thereof105922596 · CN

Funding rounds

  • EquityUndisclosed2021-08Source
  • Equity TransferUndisclosed2020-09Source
  • Series B+Undisclosed2018-07Lead: 普华资本 · Source
  • Series B~$10M2017-09Source
  • EquityUndisclosed2016-12Source

Equipment deals on record

Publicly disclosed purchases or installs only.

  • Bio-Architect SRX

    1 systems · CNY 680,000

    Buyer: Shenzhen University of Advanced Technology · Supplier: Shenzhen Boxing Biotechnology
  • 高精度3D打印机/壹套

    1 systems · CNY 765,000

    Buyer: Tongji University · Supplier: 杭州捷诺飞生物科技股份有限公司
All equipment activity

Why this company matters

AMPulse analysis, not a company disclosure

Regenovo positions itself as a complete biological 3D printing solutions provider, offering both equipment and materials to reduce tissue engineering development time. Founded in 2013 as a joint venture, it claims the world's first commercial 3D bioprinter in China and has since installed over 50 bioprinters in research institutions and hospitals across the country.

The company's core technology is material extrusion (MEX) bioprinting, applied through products like the Bio-Architect X printer. Its distinctive feature is real-time monitoring of cell microenvironments using combined OCT/ODT imaging, a capability verified by patents. Regenovo also develops proprietary bioinks and biomaterials, creating a dual-core industrial system linking biological 3D printing with biomaterials.

Customers include pharmaceutical companies, research institutions, and hospitals. Named partners include Hangzhou University of Science and Technology, Zhejiang University School of Medicine, Shanghai Ninth People's Hospital, and the Chinese Academy of Sciences. Applications span drug screening, regenerative medicine, and personalized medical devices, with published skin and micro-liver models.

Regenovo's strategic moat lies in its integrated printer-bioink platform and strong academic partnerships in China, differentiating it from global competitors like Organovo and CELLINK that focus more narrowly on bioinks or specific applications. However, its geographic concentration and reliance on government and academic funding—with $5 million raised from Shining3D and provincial sources—pose risks if commercial adoption outside research settings remains slow.